RGEN Stock Analysis — Repligen Corporation
Sector: Healthcare
AI Verdict
RGEN trades at 54.6x next year's earnings while analysts expect 151.4% EPS growth — that's a high bar, but the moat from embedded bioprocessing tech makes the growth plausible if execution holds.
Competitive Moat
Repligen supplies critical bioprocessing technologies and consumables to the biopharmaceutical industry, embedding itself in customers' manufacturing workflows. Its defensibility comes from proprietary purification and filtration products that are validated into drug production, making switching costly and risky for clients.
Summary
RGEN is notable for its 151.4% expected EPS growth next year, far outpacing most healthcare peers.
Where It Stands
RGEN has delivered 17.6% trailing revenue growth and trades at 54.6x forward earnings, more than double the healthcare sector median of 22x.
Key Metrics
- Trailing P/E: 137.2x
- Forward P/E: 54.6x
- PEG Ratio: 0.91
- Earnings Growth: +1.5%
- Revenue Growth: +0.2%
- 52-Week High: $175.77
- 52-Week Low: $109.50
Analyst Consensus
24 Buy · 5 Hold · 0 Sell (29 analysts)
Bull Case
With analysts forecasting 151.4% EPS growth, the 54.6x forward P/E is cheap for the explosive earnings rebound expected.
Bear Case
If the forward P/E compresses to the sector median of 22x, the stock could lose over 50% of its value absent the forecasted growth materializing.
Catalyst to Watch
Watch for quarterly earnings reports confirming whether the triple-digit EPS growth is on track, as any miss could trigger a sharp derating.